BIO-TECHNE CORP (TECH)       81.19  +0.87 (+1.08%)

81.19  +0.87 (+1.08%)

US09073M1045 - Common Stock - After market: 81.19 0 (0%)


Fundamental Rating

6

Taking everything into account, TECH scores 6 out of 10 in our fundamental rating. TECH was compared to 66 industry peers in the Life Sciences Tools & Services industry. TECH scores excellent points on both the profitability and health parts. This is a solid base for a good stock. TECH shows excellent growth, but is valued quite expensive already. This could make TECH a good candidate for growth investing.




Profitability

Profitability Rating

8

TECH has a Return On Assets of 12.42%. This is better than the industry average of 8.42%.
TECH's Profit Margin of 26.12% is amongst the best returns of the industry. TECH outperforms 86% of its industry peers. The industry average Profit Margin is 16.49%.

The Piotroski-F score of TECH is 8.00. This is a very strong score and indicates great health and profitability for TECH.
TECH's Return On Equity of 16.67% is in line with the rest of the industry. The industry average Return On Equity is 16.61%.
VS Industry

ROA (12.42%) VS Industry: 69% outperformed.

0.30
57.39

ROE (16.67%) VS Industry: 54% outperformed.

1.18
180.91

Profit Margin (26.12%) VS Industry: 86% outperformed.

0.20
383.95

Valuation

Valuation Rating

0

With a price book ratio of 7.28, TECH is valued correctly.
The Price/Earnings Ratio is 41.42, which means the current valuation is very expensive for TECH.
With a Price/Earning Ratio of 41.42, TECH is valued a higher than the industry average, which is at 28.09. 84% of the companies listed in the same industry are cheaper than TECH!
The Forward Price/Earnings Ratio of 32.25 indicates a quite expensive current valuation of TECH.

The high PEG Ratio, which compensates the Price/Earnings for growth, indicates TECH does not grow enough to justify the current Price/Earnings ratio.
Compared to an average industry price book ratio of 2.48, TECH is valued more expensive than its industry peers. 87% of the companies listed in the same industry are valued cheaper.
When comparing the Enterprise Value to EBITDA ratio of TECH to the average industry ratio of 20.48, TECH is valued more expensive than its industry peers.
VS Industry

Price/Earnings (41.42) VS Industry: 16% outperformed.

109.42
7.26

Price/Book (7.28) VS Industry: 13% outperformed.

51.37
0.32

Enterprise Value/ EBITDA (32.06) VS Industry: 21% outperformed.

639.94
2.24

Growth

Growth Rating

7

TECH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.41%, which is quite good.
TECH shows quite a strong growth in Earnings Per Share. Measured over the last 5 years, the EPS has been growing by 16.32% yearly.
Based on estimates for the next 5 years, TECH will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.79% on average per year.
The Revenue has grown by 13.50% in the past year. This is quite good.

The Revenue has been growing by 14.45% on average over the past 5 years. This is quite good.
Based on estimates for the next 5 years, TECH will show a quite strong growth in Revenue. The Revenue will grow by 14.36% on average per year.
When comparing the EPS growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is stable.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS16.32% 20.63% 10.41% 8.21% 12.9% 12.79% N/A
Revenue14.45% 15.69% 13.5% 8.51% 10.89% 10.79% 14.36%

Health

Health Rating

8

TECH has a Current Ratio of 4.01. This indicates that TECH is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 2.92 indicates that TECH has no problem at all paying its short term obligations.
TECH has an Altman-Z score of 14.55. This indicates that TECH is financially healthy and little risk of bankruptcy at the moment.
TECH has one of the better Altman-Z scores in its industry. It is much better than the industry average of 2.69. TECH has a better score than 93% of its industry peers.

The Piotroski-F score of TECH is 8.00. This is a very strong score and indicates great health and profitability for TECH.
The Current Ratio is in line with the industry averages, which is at 4.77.
The Quick Ratio is in line with the industry averages, which is at 4.30.
The Debt to Equity ratio of TECH is in line with the industry averages.
VS Industry

Debt/Equity (0.15) VS Industry: 42% outperformed.

3.88
0.00

Quick Ratio (2.92) VS Industry: 43% outperformed.

0.04
40.60

Current Ratio (4.01) VS Industry: 47% outperformed.

0.04
40.60

Altman-Z (14.55) VS Industry: 93% outperformed.

-152.47
23.50

Dividend

Dividend Rating

4

Compared to an average industry Dividend Yield of 0.36, TECH pays a bit more dividend than its industry peers.
17.21% of the earnings are spent on dividend by TECH. This is a low number and sustainable payout ratio.
TECH has been paying a dividend for at least 10 years, so it has a reliable track record.

With a yearly dividend of 0.39%, TECH is not a good candidate for dividend investing.
Compared to an average S&P500 Dividend Yield of 2.41, TECH's dividend is way lower than the S&P500 average.
VS Industry

Dividend Yield (0.39%) VS Industry: 71% outperformed.

0.20
0.72

BIO-TECHNE CORP81.19

NASDAQ:TECH (1/27/2023, 7:00:02 PM)+0.87 (+1.08%)

After market: 81.19 0 (0%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Life Sciences Tools & Services
Earnings (Last) 11-01 2022-11-01/bmo Earnings (Next) 01-30 2023-01-30
Inst Owners 25.66% Inst Owner Change 8.92%
Ins Owners 0.76% Ins Owner Change 13.43%
Market Cap 12.74B Analysts 83
Price Target 106.99 (31.78%)

Dividend
Dividend Yield 0.39% Dividend Growth N/A
DP 17.21% Ex-Date N/A

Surprises & Revisions
EPS beat(2) N/A Avg EPS beat(2) -3.96%
Min EPS beat(2) -4.66% Max EPS beat(2) -3.25%
EPS beat(4) 2 Avg EPS beat(4) -0.01%
Min EPS beat(4) -4.66% Max EPS beat(4) 5.04%
Revenue beat(2) N/A Avg Revenue beat(2) -3.87%
Min Revenue beat(2) -6.16% Max Revenue beat(2) -1.58%
Revenue beat(4) 1 Avg Revenue beat(4) -1.69%
Min Revenue beat(4) -6.16% Max Revenue beat(4) 1.94%
PT rev (1m) 0% EPS NQ rev (1m) N/A
EPS NY rev (1m) 0% Revenue NQ rev (1m) N/A
Revenue NY rev (1m) 0%

Valuation
Industry RankSector Rank
PE 41.42
Fwd PE 32.25
P/S 11.4
P/FCF 44.79
P/OCF 38.28
P/B 7.28
P/tB 42.45
EV/EBITDA 32.06
EPS(TTM) 1.96 EY 2.41%
EPS(NY) 2.52 Fwd EY 3.1%
FCF(TTM) 1.81 FCFY 2.23%
OCF(TTM) 2.12 OCFY 2.61%
SpS 7.12 BVpS 11.16
TBVpS 1.91 PEG (NY) 5.05
PEG (5Y) 2.54

Profitability
Industry RankSector Rank
ROA 12.42%
ROE 16.67%
ROIC 12.11%
ROICexc 13.33%
ROICexgc 47.93%
OM 26.42%
PM 26.12%
GM 68.46%
ROICexgc(3y) 46.3% ROICexcg growth 3Y 5.54%
ROICexcg growth 5Y -1.65% ROICexc(3y) 11.53%
ROICexc growth 3Y 20.01% ROICexc growth 5Y 6.6%
OM growth 3Y 8.93% OM growth 5Y 0.74%
PM growth 3Y 22.3% PM growth 5Y 12.72%
GM growth 3Y 1.05% GM growth 5Y 0.57%
F-Score 8 Asset Turnover 0.48

Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF 0.93
Debt/EBITDA 0.66
Cap/Depr 47%
Profit Quality 97.48%
Current Ratio 4.01
Quick Ratio 2.92
Altman-Z 14.55
F-Score 8 WACC 9.65%
ROIC/WACC 4.97 Cap/Depr(3y) 52.48%
Cap/Depr(5y) 44.46% Profit Quality(3y) 129.83%
Profit Quality(5y) 134.13%

Growth
EPS 1Y 10.41% EPS 3Y 20.63%
EPS 5Y 16.32% EPS growth Q2Q -2.73%
EPS Next Y 8.21% EPS Next 2Y 12.9%
EPS Next 3Y 12.79% EPS Next 5Y N/A
Revenue growth 1Y 13.5% Revenue growth 3Y 15.69%
Revenue growth 5Y 14.45% Revenue growth Q2Q 4.63%
Revenue Next Year 8.51% Revenue Next 2Y 10.89%
Revenue Next 3Y 10.79% Revenue Next 5Y 14.36%
EBIT growth 1Y 14.52% EBIT growth 3Y 26.03%
EBIT growth 5Y 15.29% EBIT Next Year 12.87%
EBIT Next 3Y 14.85% EBIT Next 5Y N/A
FCF growth 1Y 59.31% FCF growth 3Y 21.53%
FCF growth 5Y 16.89% OCF growth 1Y 44.31%
OCF growth 3Y 21.44% OCF growth 5Y 17.75%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA